Financial Performance - Q3 2025 revenue increased by 23% to $769.0 million, with U.S. Spine business growing by 10%[3] - GAAP net income for Q3 2025 was $119.0 million, a 129.5% increase year-over-year, driven by higher sales of $143.3 million[4] - Non-GAAP diluted EPS for Q3 2025 was $1.18, up 42.6% compared to $0.83 in Q3 2024[4] - Net income for Q3 2025 reached $118,966,000, a significant increase from $51,836,000 in Q3 2024, representing a growth of 129%[24] - The company reported a net income of $397.274 million for the nine months ended September 30, 2025, compared to $76.479 million in 2024, marking a significant increase of 419.5%[18] - The company’s diluted earnings per share for the nine months ended September 30, 2025, was $2.90, compared to $0.56 in 2024[18] Cash Flow and Guidance - Record non-GAAP free cash flow of $213.9 million in Q3 2025, a 24% increase quarter-over-quarter[3] - The company raised its full-year 2025 revenue guidance to $2.86 to $2.90 billion from $2.80 to $2.90 billion[6] - Non-GAAP fully diluted EPS guidance for 2025 increased to $3.75 to $3.85 from $3.00 to $3.30[6] - Free cash flow for the nine months ended September 30, 2025, was $386,378,000, an increase from $211,981,000 in the same period of 2024[38] Sales and Market Performance - International net sales grew by 16.5% year-over-year, with a 13.5% increase on a constant currency basis[3] - The Nevro acquisition contributed $99.3 million to sales, exceeding expectations and supporting future growth[4] - Base business net sales, excluding Nevro, were $669.8 million, reflecting a 7.0% increase[7] - Net sales for Q3 2025 reached $769.048 million, a 22.9% increase from $625.705 million in Q3 2024[20] - The company’s musculoskeletal solutions segment generated $741.009 million in sales for Q3 2025, up from $587.402 million in Q3 2024[20] - Net sales of Nevro products for Q3 2025 were $99,254,000, contributing to the overall sales growth[41] Profitability Metrics - Adjusted EBITDA for Q3 2025 was $252,601,000, compared to $193,691,000 in Q3 2024, reflecting a year-over-year increase of 30.4%[24] - Gross profit margin for Q3 2025 improved to 64.2%, compared to 53.0% in Q3 2024[33] - The adjusted gross profit for Q3 2025 was $523,472,000, with an adjusted gross profit margin of 68.1%[33] - The company reported a net income margin of 15.5% for Q3 2025, compared to 8.3% in Q3 2024[24] Expenses and Liabilities - Research and development expenses increased to $111.083 million for the nine months ended September 30, 2025, from $130.346 million in the same period of 2024[18] - Cash and cash equivalents decreased to $371.769 million as of September 30, 2025, down from $784.438 million at the end of 2024[21] - Total current assets were $1.924 billion as of September 30, 2025, compared to $2.177 billion at the end of 2024[17] - The company’s total liabilities decreased to $696.815 million as of September 30, 2025, from $1.074 billion at the end of 2024[17] - The company incurred merger and acquisition-related costs of $4,678,000 in Q3 2025, down from $61,160,000 in Q3 2024[28] Operating Performance - Operating income for the nine months ended September 30, 2025, was $310.476 million, compared to $105.717 million for the same period in 2024, representing a 194.5% increase[18] - Comprehensive income for the nine months ended September 30, 2025, was $415.062 million, compared to $79.708 million in 2024[18]

Exhibit 99.1 Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results DEER PARK, Ill., November 6, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2025. "The third quarter was another stellar period for Eton with product sales growing 129% year over year. The impressive results c ...

Financial Performance - Net sales for the first quarter of fiscal 2026 were $81.6 million, a decrease of $3.5 million, or 4.1%, compared to the first quarter of fiscal 2025[10] - Gross profit was $32.4 million, representing a gross margin of 39.7%, down from 43.9% in the same quarter last year[10] - The company reported a net loss of $4 million for the first quarter of fiscal 2026, an improvement from a net loss of $5 million in the first quarter of fiscal 2025[10] - Adjusted EBITDA remained flat at $1.4 million for both the first quarter of fiscal 2026 and the first quarter of fiscal 2025[10] - Operating expenses decreased to $35.6 million, or 43.6% of net sales, compared to $40.1 million, or 47.2%, in the first quarter of fiscal 2025[10] - Net loss for the three months ended September 30, 2025, was $4,025,000, an improvement from a net loss of $5,002,000 in the same period of 2024[20] - EBITDA for the same period was $(751,000), compared to $(1,408,000) in 2024, resulting in an EBITDA margin of (0.9)%[26] - Adjusted EBITDA for the three months ended September 30, 2025, was $1,364,000, consistent with an Adjusted EBITDA margin of 1.7%[28] Cash Flow and Assets - The company had $3.8 million in unrestricted cash and cash equivalents as of September 30, 2025[5] - Cash flows from operating activities showed a net cash used of $5,007,000, a decline from net cash provided of $2,493,000 in 2024[20] - Cash and cash equivalents at the end of the period were $3,999,000, down from $5,138,000 at the end of the same period in 2024[20] - The company experienced a net decrease in cash and cash equivalents of $2,975,000, compared to a decrease of $867,000 in the prior year[20] - As of September 30, 2025, total assets were $158.8 million, a decrease from $161.2 million as of June 30, 2025[18] Strategic Initiatives - Farmer Brothers announced a partnership with Eurest to open 50 Sum>One Coffee Roasters-branded cafes across the country[10] - The company maintained a focus on driving top-line revenue and customer growth in 2026 despite a challenging economic environment[3] - The company incurred $587,000 in strategic initiative costs during the quarter, which were not present in the previous year[28] Expenses - There was a nearly $4 million improvement in sales, general, and administrative (SG&A) expenses compared to the first quarter of fiscal 2025[10] - Depreciation and amortization expense for the quarter was $2,614,000, compared to $2,897,000 in 2024[26] - The company reported a net cash used in investing activities of $1,919,000, an improvement from $3,304,000 in the prior year[20] - Proceeds from credit facilities amounted to $4,000,000, compared to $3,000,000 in the same period of 2024[20]

Financial Performance - Amphastar reported net revenues of $191.8 million for the three months ended September 30, 2025, a slight increase of 0.3% compared to $191.2 million in the same period last year[3]. - GAAP net income for the third quarter was $17.4 million, or $0.37 per share, down from $40.4 million, or $0.78 per share, in the prior year[5]. - Adjusted non-GAAP net income was $44.7 million, or $0.93 per share, compared to $49.6 million, or $0.96 per share, in the same quarter last year[5]. - Total net revenues for Q3 2025 were $191,840,000, a slight increase from $191,214,000 in Q3 2024, representing a growth of 0.3%[25]. - Product revenues for the nine months ended September 30, 2025, reached $536,782,000, compared to $525,836,000 for the same period in 2024, indicating a growth of 2.8%[25]. - GAAP net income for Q3 2025 was $17,350 million, a decrease of 57.1% compared to $40,429 million in Q3 2024[29]. - Adjusted non-GAAP net income for the nine months ended September 30, 2025, was $122,460 million, down 20.3% from $153,569 million in the same period of 2024[29]. - Total GAAP revenue for the nine months ended September 30, 2025, was $266,395 million, an increase of 3.8% from $258,237 million in 2024[30]. Revenue Drivers - BAQSIMI® sales increased by 33% to $53.6 million, driven by higher unit volumes and expanded marketing efforts[4]. - Total product revenues increased by 2% to $191.8 million, with notable declines in glucagon and epinephrine sales due to pricing pressures and competition[4]. - The company received FDA approval and launched iron sucrose injection, contributing to revenue growth and expanding patient access[3]. Expenses - Research and development expenses increased by 6% to $22.4 million, primarily due to a $5.3 million upfront payment for a licensing agreement with Nanjing Anji Biotechnology[12]. - Selling, distribution, and marketing expenses rose by 28% to $11.5 million, reflecting expanded sales efforts related to BAQSIMI®[9]. - Operating expenses increased to $73,326,000 in Q3 2025 from $44,893,000 in Q3 2024, marking a significant rise of 63.5%[25]. - Selling, general, and administrative expenses for the nine months ended September 30, 2025, totaled $69,454 million, an increase of 58.7% from $43,782 million in 2024[30]. - Research and development expenses for the nine months ended September 30, 2025, were $60,114 million, compared to $53,579 million in 2024, indicating a rise of 12.1%[30]. Assets and Liabilities - Cash and cash equivalents as of September 30, 2025, were $216,265,000, up from $151,609,000 at the end of 2024, showing an increase of 42.6%[27]. - Total assets increased to $1,666,222,000 as of September 30, 2025, compared to $1,577,470,000 at the end of 2024, representing a growth of 5.6%[27]. - Total liabilities stood at $889,476,000 as of September 30, 2025, compared to $845,172,000 at the end of 2024, indicating an increase of 5.2%[27]. Income and Tax - The company reported a basic net income per share of $0.38 for Q3 2025, down from $0.83 in Q3 2024[25]. - Non-GAAP operating income for Q3 2025 was $85,672 million, compared to $81,981 million in Q3 2024, reflecting a growth of 4.2%[29]. - The company incurred a litigation provision of $23,147 million in Q3 2025, which was not present in Q3 2024[29]. - Income tax provision on pre-tax adjustments for the nine months ended September 30, 2025, was $14,202 million, compared to $8,912 million in 2024, reflecting a rise of 59.5%[30].

Financial Performance - TTEC's Q3 2025 revenue was $519.1 million, a decrease of $10.3 million or 1.9% compared to Q3 2024, with TTEC Digital contributing $121.9 million (23%) and TTEC Engage $397.2 million (77%) to total revenue [160]. - TTEC Digital segment revenue increased by $6.2 million or 5.4% to $121.9 million in Q3 2025, while TTEC Engage segment revenue decreased by $16.5 million or 4.0% to $397.2 million [164]. - Operating income for TTEC Digital decreased to $4.9 million (4.0% margin) in Q3 2025 from $7.5 million (6.5% margin) in Q3 2024, primarily due to lower margins in recurring business [175]. - TTEC Engage's operating income increased to $7.5 million (1.9% margin) in Q3 2025 from $5.4 million (1.3% margin) in Q3 2024, attributed to lower impairment expenses [177]. - For the nine months ended September 30, 2025, TTEC Digital revenue was $343.7 million, a slight decrease of $0.4 million or 0.1%, while operating income increased by $5.4 million or 32.0% to $22.1 million [182]. - TTEC Engage revenue for the nine months ended September 30, 2025 was $1.2 billion, a decrease of $72.8 million or 5.6%, with operating income improving to $33.3 million from a loss of $205.6 million [184]. Interest and Other Income - Interest income for Q3 2025 increased to $0.5 million from $0.3 million in Q3 2024, while interest expense decreased to $16.6 million from $21.7 million due to lower utilization and rates [178]. - Other income for Q3 2025 was $3.8 million, a significant increase from an expense of $1.0 million in Q3 2024, including a $1.7 million gain from an aged VAT receivable recovery [179]. Taxation - The effective tax rate for Q3 2025 was 21,930.3%, compared to (98.1)% in Q3 2024, influenced by income distribution across jurisdictions and foreign currency gains [180]. - The effective tax rate for the nine months ended September 30, 2025, was 189.9%, compared to (26.4)% for the same period in 2024 [188]. Cash Flow and Capital Expenditures - Operating cash flows for the nine months ended September 30, 2025, were $118.5 million, a significant increase from $(57.7) million in 2024 [189][195]. - Cash and cash equivalents decreased to $73.5 million as of September 30, 2025, down from $85.0 million at the end of 2024 [194]. - Free cash flow for the nine months ended September 30, 2025, was $92.1 million, compared to $(94.2) million for the same period in 2024 [198]. - Net cash flows used in investing activities decreased to $21.9 million for the nine months ended September 30, 2025, from $36.3 million in 2024 [196]. - Net cash flows provided by/(used in) financing activities were $(102.9) million for the nine months ended September 30, 2025, compared to $14.8 million in 2024, primarily due to a $(122.5) million net change in the line of credit [197]. - Total capital expenditures in 2025 are expected to be between 1.8% and 2.0% of revenue, with 55% allocated for business growth and 45% for maintenance [202]. - The company anticipates that the amount of capital required over the next 12 months will depend on investment levels in infrastructure and potential acquisitions [203]. Client Relationships - The company has long-term relationships with its top five clients, which accounted for 31.8% of consolidated revenue for the three months ended September 30, 2025 [204]. - Some contracts with the five largest clients expire between 2026 and 2029, but the company has historically renewed most contracts [205]. - One client represented more than 10% of total revenue during the nine months ended September 30, 2025 and 2024 [204]. - The five largest clients accounted for 31.8% and 31.5% of consolidated revenue for the three months ended September 30, 2025 and 2024, respectively [204]. - For the nine months ended September 30, 2025 and 2024, the five largest clients represented 31.0% and 32.6% of consolidated revenue, respectively [204]. - Long-term relationships with top five clients range from 6 to 23 years, with multiple contract renewals completed [204]. - Contracts with the five largest clients expire between 2026 and 2029, with many clients having multiple contracts with different expiration dates [205]. - Historical renewal rate of contracts with largest clients is high, but future renewals are not guaranteed [205].

Financial Performance - Kronos Worldwide reported a net loss of $37.0 million, or $0.32 per share, in Q3 2025, compared to a net income of $71.8 million, or $0.62 per share, in Q3 2024[1]. - Net sales for Q3 2025 were $456.9 million, a decrease of $27.8 million, or 6%, compared to Q3 2024; for the first nine months of 2025, net sales were $1.4 billion, down $22.9 million, or 2%, from the same period in 2024[1]. - EBITDA for Q3 2025 was $0.6 million, a significant decrease from $123.3 million in Q3 2024; for the first nine months of 2025, EBITDA was $74.0 million, down from $211.2 million in the same period in 2024[3]. - Gross margin improved to $101.2 million in Q3 2024 from $47.0 million in Q3 2025, reflecting a significant operational efficiency[11]. - Net income for Q3 2024 was $71.8 million, compared to a net loss of $37.0 million in Q3 2025, indicating a strong recovery[11]. - EBITDA for Q3 2024 was $123.3 million, significantly higher than $0.6 million in Q3 2025, showcasing improved profitability[13]. Sales and Pricing - Average TiO2 selling prices declined by 6% in Q3 2025 compared to Q3 2024 and by 2% in the first nine months of 2025 compared to the same period in 2024[1]. - TiO2 sales volume decreased by 3% in Q3 2025 compared to Q3 2024, while total net sales saw a 6% decline[14]. - Currency fluctuations, primarily the euro, increased net sales by approximately $14 million in Q3 2025 and by approximately $11 million in the first nine months of 2025 compared to the same prior year periods[1]. Segment Performance - The TiO2 segment reported a loss of $15.3 million in Q3 2025, compared to a profit of $43.4 million in Q3 2024; for the first nine months of 2025, segment profit was $37.2 million, down from $107.9 million in the same period in 2024[2]. - Unabsorbed fixed production costs related to decreased production volumes in Q3 2025 were approximately $27 million, contributing to the segment loss[2]. - Production volumes for TiO2 remained stable at 141,000 metric tons in Q3 2024, compared to 126,000 metric tons in Q3 2025[11]. Operational Efficiency - The company operated its production facilities at an average capacity utilization of 85% in the first nine months of 2025, down from 93% in the same period in 2024[2]. - Selling, general and administrative expenses increased slightly to $62.3 million in Q3 2024 from $61.6 million in Q3 2025[11]. Strategic Developments - The company acquired the remaining 50% interest in Louisiana Pigment Company, L.P. in July 2024, which is now a wholly-owned subsidiary[1]. - The company reported a gain of $64.5 million on the remeasurement of its investment in TiO2 manufacturing joint venture[11]. Risks and Challenges - The company faces risks including supply and demand fluctuations, geopolitical tensions, and changes in raw material costs that could impact future performance[5]. - The company experienced a 3% increase in currency exchange rates, positively impacting overall sales[14].

Product Development and Approvals - PALSONIFY™ (paltusotine) was approved by the FDA on September 25, 2025, for the treatment of acromegaly, with a marketing authorization application under review by the EMA[88][89]. - Approximately 36,000 people in the U.S. are living with acromegaly, with 17,000 undiagnosed and 11,500 actively managed; 40% of actively managed patients are treatment naïve[88]. - Atumelnant showed significant clinical improvements in a Phase 2 study for congenital adrenal hyperplasia, with data expected early in 2026[92]. - The company expects to initiate a Phase 2/3 trial of atumelnant for ACTH-Dependent Cushing's Syndrome in the first half of 2026[92]. - The first patient for CRN09682, a candidate for treating neuroendocrine tumors, is expected to be enrolled in a Phase 1/2 study in Q4 2025[92]. Financial Performance - The company has not generated any product revenue during the quarter ended September 30, 2025, despite FDA approval of PALSONIFY[95][96]. - Revenues for the nine months ended September 30, 2025, were derived from licensing agreements, with no revenues from PALSONIFY sales[100]. - Revenues for the three months ended September 30, 2025, were $143,000, a 100% increase from $0 in the same period of 2024; revenues for the nine months ended September 30, 2025, were $1,535,000, a 48% increase from $1,039,000 in 2024[107]. Operating Expenses - Cumulative net losses have been incurred since inception, with expectations of increased operating expenses as product revenues grow[96]. - Research and development expenses primarily relate to the clinical development of paltusotine and atumelnant, with significant costs expected to continue[101]. - Research and development expenses increased by $28.6 million (46%) for the three months ended September 30, 2025, and by $73.4 million (42%) for the nine months ended September 30, 2025, compared to the prior year periods[108]. - Selling, general and administrative expenses rose by $26.4 million (102%) for the three months ended September 30, 2025, and by $66.1 million (92%) for the nine months ended September 30, 2025, compared to the prior year periods[112]. - The total operating expenses for the three months ended September 30, 2025, were $142.7 million, a 63% increase from $87.8 million in the same period of 2024; for the nine months ended September 30, 2025, total operating expenses were $384.6 million, a 57% increase from $245.1 million in 2024[107]. - Clinical trial expenses increased by $7.2 million (71%) for the three months ended September 30, 2025, and by $14.5 million (49%) for the nine months ended September 30, 2025, compared to the prior year periods[110]. - Contract manufacturing expenses rose by $3.0 million (43%) for the three months ended September 30, 2025, and by $7.2 million (38%) for the nine months ended September 30, 2025, compared to the prior year periods[110]. Net Loss and Cash Flow - The net loss for the three months ended September 30, 2025, was $130.1 million, a 69% increase from $76.8 million in the same period of 2024; for the nine months ended September 30, 2025, the net loss was $342.5 million, a 57% increase from $217.8 million in 2024[107]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $285.0 million, a 75% increase from $163.3 million in the same period of 2024[120]. - Net cash provided by investing activities increased significantly to $116.8 million for the nine months ended September 30, 2025, compared to a cash outflow of $32.7 million in 2024[120]. - Net cash provided by financing activities decreased by 97% to $14.6 million for the nine months ended September 30, 2025, down from $458.4 million in 2024[120]. Capital and Financing - The company plans to finance cash needs through equity offerings and collaborations until significant product revenues are generated[97]. - The company may need to raise substantial additional capital in the future to support ongoing and future product development[103]. - The company anticipates financing cash needs through equity offerings, debt financings, or collaborations, which may dilute existing stockholder interests[117]. - The company has entered into a Sales Agreement for an ATM Offering of up to $350.0 million, but no shares have been sold under this agreement as of the report date[118]. Cash and Investment Securities - As of September 30, 2025, cash and cash equivalents decreased by 58% to $110.9 million compared to $264.5 million as of December 31, 2024[115]. - Investment securities decreased by 10% to $981.4 million as of September 30, 2025, down from $1.1 billion as of December 31, 2024[115]. - The accumulated deficit increased by 36% to $1.3 billion as of September 30, 2025, compared to $952.1 million as of December 31, 2024[115]. Shareholder Information - As of October 28, 2025, the company had 94.9 million outstanding shares of common stock[119].

Financial Performance - Net sales for Q3 2025 were $250.9 million, a decrease of 14.3% from $292.8 million in Q3 2024[5] - Gross profit was $100.8 million, resulting in a gross margin of 40.2%, compared to a gross margin of 40.9% in the previous year[6] - Net income for Q3 2025 was $0.9 million, or $0.02 per diluted share, down from $4.6 million, or $0.08 per diluted share in Q3 2024[6] - Adjusted EBITDA for Q3 2025 was $24.4 million, compared to $31.0 million in Q3 2024[6] - Funko, Inc. reported a net loss of $68,115,000 for the nine months ended September 30, 2025, compared to a net loss of $13,650,000 for the same period in 2024[22] - Adjusted EBITDA for the nine months ended September 30, 2025, was $3,238,000, a decrease from $68,476,000 for the same period in 2024[23] - The company reported an adjusted net loss margin of 6.5% for the nine months ended September 30, 2025, compared to 0.6% for the same period in 2024[23] Debt and Liabilities - Total debt increased to $241.0 million as of September 30, 2025, up from $182.8 million at the end of 2024[11] - The company's total liabilities rose significantly to $641,658,000 as of September 30, 2025, compared to $470,097,000 as of December 31, 2024, marking an increase of 36.5%[20] - Funko, Inc. experienced a significant increase in the line of credit, which rose to $135,000,000 as of September 30, 2025, compared to $60,000,000 as of December 31, 2024[20] Assets and Equity - Total current assets increased to $299,943,000 as of September 30, 2025, up from $287,059,000 as of December 31, 2024, representing a growth of 4.5%[20] - Cash and cash equivalents at the end of the period were $39,177,000, an increase from $34,655,000 at the beginning of the period, reflecting a net change of 11.5%[21] - The company’s total stockholders' equity attributable to Funko, Inc. decreased to $182,684,000 as of September 30, 2025, down from $233,019,000 as of December 31, 2024, a decline of 21.6%[20] Inventory and Expenses - Inventories increased to $99.8 million at September 30, 2025, from $92.6 million at December 31, 2024[11] - SG&A expenses were $79.8 million, including a non-recurring charge of $1.0 million, compared to $92.7 million with a non-recurring charge of $0.4 million in the prior year[6] - Funko, Inc. recorded depreciation and amortization expenses of $44,319,000 for the nine months ended September 30, 2025, slightly down from $46,409,000 in 2024[22] - The company’s inventories increased to $99,805,000 as of September 30, 2025, up from $92,580,000 as of December 31, 2024, indicating an increase of 7.3%[20] Strategic Initiatives - The Bitty Pop! line contributed significantly to sales, being featured on Walmart's 2025 Top Toy List[3] - The company expects modest net sales growth from Q3 2025 and a gross margin of approximately 40% for Q4 2025[11] - The company plans to continue expanding into new fandoms and enhancing retail experiences as part of its Make Culture POP! strategy[4]

Exhibit 99.2 Non-US GAAP Financial Measures and Supplemental Information This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain. Use of Non-US GAAP Financial Measures From time to time, management may publicly disclose certain numerical "non-GAAP financial measures" in the course of our earnings releases, financial presentations, earnings conference calls, investor and analyst meetings and otherwise. For these purposes, the Securities and Exchange Commission (" ...

Financial Performance - Cherry Hill reported GAAP net income applicable to common stockholders of $2.0 million, or $0.05 per share for Q3 2025[6] - Earnings available for distribution (EAD) attributable to common stockholders were $3.3 million, or $0.09 per diluted share[5] - Comprehensive income attributable to common stockholders was $4.48 million for Q3 2025[9] Dividends - The declared regular common dividend was $0.10 per share, resulting in an annualized common dividend yield of 17.0%[6] Portfolio Metrics - The common book value per share was $3.36 as of September 30, 2025[6] - The aggregate portfolio leverage stood at 5.3x as of September 30, 2025[6] - The unpaid principal balance for the MSR portfolio was $16.2 billion, with a carrying value of $218.7 million[10] - The RMBS portfolio had a book value of approximately $1.2 billion, with a weighted average coupon of 4.98%[11] Risk Management - The company held interest rate swaps with a notional amount of $828.7 million to mitigate duration risk[12] Strategic Goals - The company is committed to strategically growing its portfolio while delivering attractive risk-adjusted returns for shareholders[4]